Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
Reading Time: 7 minutes Zug, Switzerland: Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology, showing the trial met all primary and key secondary endpoints1
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024
Reading Time: < 1 minute Stock Exchange Release 28.11.2024 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024 Date 28.11.2024 Exchange transaction Buy Share class FSKRS Amount 300 Average price/share 14.8196 EUR Highest price/share 14.8200 EUR Lowest price/share
The board of Peptonic resolves, subject to the approval a subsequent general meeting, on a rights issue of units of approximately SEK 26.5 million
Reading Time: 9 minutes NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PEPTONIC MEDICAL AB
Reading Time: 11 minutes N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall
SyntheticMR resolves on a rights issue of approximately SEK 65 million
Reading Time: 12 minutes THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR
Notice of extra general meeting in SyntheticMR AB (publ)
Reading Time: 8 minutes The shareholders of SyntheticMR AB (publ), reg. no. 556723-8877, (the “Company“) are hereby invited to the extra general meeting on Tuesday 17 December 2024 at 13:00 CET at the Company’s premises on Storgatan 11 in Linköping. Right to attend the general
SyntheticMR signs agreement to acquire Finnish Combinostics Oy
Reading Time: 6 minutes 28 November 2024, 22:55 CET SyntheticMR AB (“SyntheticMR” or the “Company”) has signed an agreement to acquire Finnish Combinostics Oy (“Combinostics”), through the acquisition of all shares in Combinostics, a leading medical technology and software solutions company focusing on cloud-based and AI-driven
Inside information, profit warning: Fondia Plc lowers its guidance on the outlook for 2024
Reading Time: < 1 minute Fondia Plc Company release, inside information 28.11.2024 at 10.10 p.m. EET Fondia lowers its outlook published on September 11, 2024, on net sales and operating profit for 2024 due to the continued difficult and uncertain market situation. The signs of
Fondia Plc: Share repurchase 28.11.2024
Reading Time: < 1 minute Fondia Plc Company release 28.11.2024 at 6.45 p.m. EET Fondia – Acquisition of own shares 28.11.2024 Fondia Plc First North Finland Date 28.11.2024 Exchange transactions Buy Share class FONDIA Amount, shares 269 Average price/share, EUR 5,660037
Roc Oil Company Pty Limited has received necessary regulatory approvals in Oman for the recommended cash offer to the shareholders of Tethys Oil AB
Reading Time: 9 minutes THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT